AstraZeneca Holds Preliminary Talks with Bristol Myers Squibb on Potential $400 Billion Merger
oncodaily - A deal that could create the world’s fourth-largest drugmaker British pharmaceutical leader AstraZeneca has held confidential, preliminary discussions regarding a potential combination with US rival Bristol Myers Squibb(BMS). A completed […]
AI Summary: AstraZeneca entered preliminary, non-binding talks with Bristol Myers Squibb about a potential $400 billion merger, probing whether combining pipelines and scale could reshape oncology and other businesses. The discussions are early, sparking market speculation and likely regulatory scrutiny as executives weigh strategic synergies against integration complexity and antitrust risk.
Fridge-free tetanus-diphtheria vaccine shows promise of reaching millions worldwide
medicalxpress - The encouraging results of the world's first trial of a fridge-free tetanus-diphtheria vaccine could improve access worldwide to crucial treatments while reducing carbon emissions. Fridge-free vaccines have the potential to transform vaccine delivery by r…
AI Summary: Early studies of fridge‑free vaccine formulations, including a tetanus‑diphtheria candidate, indicate stability without cold storage, promising to reduce discarded doses and simplify distribution in low‑resource settings. If these results hold up, the change could shrink logistical headaches, boost global immunization reach and finally make the vaccine refrigerator’s light a little less terrifying.
FDA Approved Pluvicto Plus ARPI for PSMA-Positive mAPMN/S Prostate Cancer
oncodaily - On July 31, 2026, the US Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan, marketed as Pluvicto, in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults […]
AI Summary: The FDA has approved an expanded use for a lutetium‑177 radiopharmaceutical (Pluvicto), broadening access for PSMA‑positive metastatic prostate cancer patients and potentially speeding the adoption of targeted radionuclide therapy. Clinicians note the approval could shift treatment sequencing and patient pathways, with implementation details and eligibility criteria guiding real‑world impact.
- Access, dose optimization and real-world data for Lu-177 (4)
- FDA expands Pluvicto approval; industry reaction (3)
- PSMAddition trial: earlier Lu-177 delays metastatic progression (5)
Access, dose optimization and real-world data for Lu-177
FDA expands Pluvicto approval; industry reaction
PSMAddition trial: earlier Lu-177 delays metastatic progression
Mel Mann Highlights First Patient Enrollment in AACR-ADOPT-GEA Trial
oncodaily - Mel Mann, World’s Longest Living Gleevec (Imatinib) / TKI Survivor, 31-year terminal Chronic Myeloid Leukemia (CML) Survivor, Clinical Trial Pioneer, and Patient Advocate, shared American Association for Cancer Research (AACR) […]
AI Summary: The AACR‑affiliated ADOPT‑GEA phase II trial for locally advanced gastroesophageal cancer has reported its first patient enrollment, marking a key milestone in the study's launch. The enrollment signals trial readiness and opens recruitment momentum to evaluate investigational approaches for a challenging cancer subtype, advancing potential new treatment options toward evidence‑based use.
Single dose of psilocybin for depression shows promising results in UK's first publicly funded randomized trial
medicalxpress - The first randomized controlled trial in the U.K. has found that a single dose of psilocybin, the active compound found in "magic mushrooms," produced significant improvements in depression compared with a placebo. This is the first publicly funded random…
AI Summary: A publicly funded randomized trial in the UK found that a single dose of psilocybin, delivered in a clinical setting, produced promising improvements for people with treatment-resistant major depressive disorder. The results suggest psychedelic-assisted therapy could be a viable addition to standard care—pending larger trials and careful safety monitoring—challenging old assumptions about one-and-done fixes.
FDA approves first drug for full range of narcolepsy symptoms
medicalxpress - The U.S. Food and Drug Administration has approved Orzeyful (oveporexton) tablets to treat narcolepsy type 1 in adults. Orzeyful marks the first medication approved for the full range of symptoms associated with narcolepsy type 1 and is the first approved…
AI Summary: The FDA has approved a medication that treats the full range of narcolepsy symptoms, including excessive daytime sleepiness and cataplexy, marking the first such comprehensive option for patients with narcolepsy type 1. Clinicians now have a single, regulated choice to address multiple debilitating symptoms rather than juggling piecemeal therapies.
International project delivers hundreds of next-generation models for cancer research
medicalxpress - Ten years and thousands of patient samples later, the National Cancer Institute (NCI) has published its results from the Human Cancer Model Initiative (HCMI) on the development of 665 organoid models of 25 types of cancer that are now available to scienti…
AI Summary: An international consortium released hundreds of patient‑derived tumor models, including a public HCMI set of 665 organoids, creating a living biobank for drug discovery. Labs worldwide now gain access to diverse, next‑generation models to test therapies and probe cancer vulnerabilities — a major boost for preclinical translational work.
- Experts react: three Nature papers and model summaries (3)
- HCMI release: 665 organoids unveiled in Nature (4)
- Organoids power maps and predictors of therapy resistance (4)
Experts react: three Nature papers and model summaries
HCMI release: 665 organoids unveiled in Nature
Organoids power maps and predictors of therapy resistance
New bipartisan 340B reform bill curbs HHS' rebate pilot
fiercehealthcare - The SUSTAIN 340B Act introduced Wednesday would bring hospital-backed changes, like a clearinghouse to handle improper discounts, and codifies longstanding grey areas in the contentious subsidy program.
AI Summary: Bipartisan lawmakers introduced legislation to rein in HHS’s controversial 340B rebate pilot, pushing back on administrative changes that providers say threaten safety‑net funding. The bill aims to pause or limit the pilot while stakeholders debate drug‑pricing impacts, reimbursements and patient access — the predictable Washington policy scrum.